Target intelligence / Profile preview

Cyclophilin peptidyl-prolyl isomerase (Cyp)

Target
Cyp
Molecular classification
Enzyme, Peptidyl-prolyl cis-trans isomerase, Immunophilin
01

Overview

Cyclophilin peptidyl-prolyl isomerases are a large family of enzymes (immunophilins) found ubiquitously in prokaryotes and eukaryotes. They catalyze the rate-limiting cis-trans isomerization of peptide bonds at proline residues, thereby accelerating protein folding and influencing the assembly and function of multidomain proteins. Cyclophilins also act as molecular chaperones, participate in intracellular signaling, immune regulation, apoptosis, and cell migration. Their extracellular secretion contributes to inflammatory signaling. Cyclophilins are therapeutic targets for drugs such as cyclosporin, which inhibit their enzymatic activity and suppress immune responses critical for organ transplantation and autoimmune diseases. Dysregulation or overexpression of cyclophilins is implicated in neurodegenerative disorders, cancer, cardiovascular disease, infection, and aging. Specific isoforms, especially cyclophilin A (CypA), play pivotal roles in disease mechanisms and are being explored as biomarkers and drug targets.

Other names
Peptidylprolyl isomeraseCyclophilin ACyclophilin BRotamaseImmunophilin
02

Mechanism of action

Enzyme inhibition (Drug binds to cyclophilin active site, blocking peptidyl-prolyl isomerase activity); Immunosuppression (CsA-cyclophilin complex inhibits calcineurin phosphatase, suppressing T-cell activation)

03

Biological functions

Protein foldingChaperone/Foldase activityIntracellular signalingTranscription regulationImmune responseApoptosisCell cycle regulationCell migration and proliferation
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular disease (e.g., atherosclerosis)Inflammatory diseases (e.g., arthritis)Viral infection (e.g., HIV, hepatitis B/C)Aging
05

Safety considerations

Immunosuppression riskPotential off-target effects due to broad expression
06

Interacting drugs

Cyclosporin A (CsA)
07

Biomarkers

Cyclophilin A (CypA) levels in plasma/serum

Beyond the preview

Go deeper on Cyclophilin peptidyl-prolyl isomerase (Cyp).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclophilin peptidyl-prolyl isomerase (Cyp).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call